Oculis Announces Supportive FDA Pre-IND Feedback For Privosegtor In Multiple Sclerosis; Stock Up

Oculis Holding AG(OCS) announced positive U.S. Food and Drug Administration (FDA) pre-Investigational New Drug (IND) feedback regarding Privosegtor's clinical development plan in acute multiple sclerosis (MS) relapses.